Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...